The use of HMG-CoA inhibitors (statins), known to reduce lipoprotein levels and risk of cardiovascular events, has been shown to reduce mRNA levels of both IL1α and IL1β in peripheral blood mononuclear cells (PBMCs) [17] providing further evidence of an interplay between IL-1 and hypercholesterolaemia. This evidence concerns the gene IL1B and Hypercholesterolemia.